1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAlzheimer's Disease Research is sponsored by BrightFocus Foundation. This program drives innovative research worldwide to defeat Alzheimer's disease and related dementias. It provides initial funding for highly innovative, experimental research and creative ideas to spark revolutionary approaches and life-saving breakthroughs.
Get alerted about grants like this
Save a search for “BrightFocus Foundation” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Alzheimer's Disease Research Request for Proposals | BrightFocus Foundation Alzheimer’s Disease Research Request for Proposals Alzheimer’s Disease Research, a BrightFocus Foundation program, provides research funds for U.S. domestic and international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of Alzheimer’s disease.
We are committed to supporting scientists from diverse backgrounds to foster creativity and innovation in addressing complex scientific challenges and strongly encourage applications from individuals who are from groups underrepresented in Alzheimer’s disease research. Explore Recently Funded Research Request for Proposals Opens All deadlines are 5:00 p. m.
EST (Washington, D. C.) on the day of the deadline.
Please note that a Letter of Intent is no longer required for this program. Applicants must submit a full proposal by the stated deadline. Application guidelines, instructions, and eligibility criteria will be available when applications open.
Alzheimer’s Disease Research offers two types of awards: Postdoctoral Fellowship Awards Must be within 5 years of degree conferral. Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards fund projects in an established laboratory that will serve as the basis for the applicant’s independent research career.
Within 5 years of degree conferral Application guidelines, instructions, and eligibility criteria will be available when applications open. This research grant program is restricted to new and early investigators who have obtained their MD, PhD, or equivalent degree and/or completed formal medical training/residency within the past 12 years at the time of application.
The applicant must serve as the principal investigator on the project, have institutional permission to manage the award, and the key personnel associated with the proposal. Early Career Investigator Track: Within 15 years of degree conferral Independent Investigator Track: Applicants from outside the Alzheimer’s field and cross-disciplinary approaches are strongly encouraged.
Applicants should not hold an active R01 (or equivalent) for the same of closely related research topic. This program is highly competitive and prioritizes innovation. Application guidelines, instructions, and eligibility criteria will be available when applications open.
Browse related Alzheimer’s disease research news and information. Can Better Sleep Slow Alzheimer’s? New BrightFocus-funded research suggests restoring sleep may help protect the brain from dementia progression, and a common insomnia drug could help lead the way.
Breaking News Dispatch: Alzheimer’s Oral Therapies, Prevention Strategies, and Targeted Treatments Emerge Get the latest research news from the 2026 International Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) conference. Can Targeting the Immune System Slow the Progression of Alzheimer’s?
BrightFocus Alzheimer’s Disease Research grant recipient Joshua Emmerson, PhD, is exploring a certain type of immune cell’s unexpected role in Alzheimer’s disease—and what it could mean for protecting the brain. Unlocking the Brain’s Regenerative Potential to Fight Alzheimer’s María Llorens-Martín is investigating why the brain stops making new cells in Alzheimer’s—and how fixing that process could change lives.
Breaking News Dispatch: New Findings on GLP-1 Drugs and Alzheimer’s, Novel Treatments in Development, and More Get the latest news from the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) conference. 4 Takeaways from Alzheimer’s Fast Track 2025 This innovative meeting hosted by BrightFocus Foundation bridges cutting-edge science, mentorship, and community building for early-career researchers.
Understanding Alzheimer’s & Exploring New Frontiers in Treatment Watch a conversation inspired by the documentary film Taking Care and the latest research in Alzheimer’s therapies.
New Clues in the Fight Against Alzheimer’s: Q&A with Dr. Keith Hengen During World Alzheimer’s Month, Alzheimer’s Disease Research grantee Dr. Keith Hengen joined BrightFocus’ Dr. Sharyn Rossi on Instagram Live to talk brain health—how the brain functions, why quality sleep matters, and tips to keep your brain healthy.
Targeting Genetic Triggers of Inflammation in Alzheimer’s Disease A BrightFocus Alzheimer’s Disease Research-funded scientist is investigating how “jumping genes” may fuel brain inflammation in Alzheimer’s—and whether blocking them could prevent or slow dementia. Can Better Sleep Slow Alzheimer’s?
New BrightFocus-funded research suggests restoring sleep may help protect the brain from dementia progression, and a common insomnia drug could help lead the way. Breaking News Dispatch: Alzheimer’s Oral Therapies, Prevention Strategies, and Targeted Treatments Emerge Get the latest research news from the 2026 International Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) conference.
Can Targeting the Immune System Slow the Progression of Alzheimer’s? BrightFocus Alzheimer’s Disease Research grant recipient Joshua Emmerson, PhD, is exploring a certain type of immune cell’s unexpected role in Alzheimer’s disease—and what it could mean for protecting the brain.
Unlocking the Brain’s Regenerative Potential to Fight Alzheimer’s María Llorens-Martín is investigating why the brain stops making new cells in Alzheimer’s—and how fixing that process could change lives. Breaking News Dispatch: New Findings on GLP-1 Drugs and Alzheimer’s, Novel Treatments in Development, and More Get the latest news from the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) conference.
4 Takeaways from Alzheimer’s Fast Track 2025 This innovative meeting hosted by BrightFocus Foundation bridges cutting-edge science, mentorship, and community building for early-career researchers. Understanding Alzheimer’s & Exploring New Frontiers in Treatment Watch a conversation inspired by the documentary film Taking Care and the latest research in Alzheimer’s therapies.
New Clues in the Fight Against Alzheimer’s: Q&A with Dr. Keith Hengen During World Alzheimer’s Month, Alzheimer’s Disease Research grantee Dr. Keith Hengen joined BrightFocus’ Dr. Sharyn Rossi on Instagram Live to talk brain health—how the brain functions, why quality sleep matters, and tips to keep your brain healthy.
Targeting Genetic Triggers of Inflammation in Alzheimer’s Disease A BrightFocus Alzheimer’s Disease Research-funded scientist is investigating how “jumping genes” may fuel brain inflammation in Alzheimer’s—and whether blocking them could prevent or slow dementia.
Based on current listing details, eligibility includes: Researchers worldwide (specifics for non-profits should be confirmed on funder's site). Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Unspecified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
BrightFocus Foundation Alzheimer's Disease Research Grants is a grant from BrightFocus Foundation that funds pioneering biomedical research aimed at understanding, preventing, and treating Alzheimer's disease. The program supports both U.S. domestic and international researchers conducting early-stage and translational research across the stages of discovery. Priority areas include molecular mechanisms of disease, novel therapeutic targets, and clinical interventions. Eligible applicants include scientists and institutions worldwide. Awards support multi-year research projects, with funding levels and deadlines announced annually via a Request for Proposals.
Macular Degeneration Innovative Research Grants is sponsored by BrightFocus Foundation. This program funds high-risk/high-gain age-related macular degeneration research, prioritizing innovative, "outside-the-box" ideas—especially from investigators new to the field. It is ideal for established investigators. BrightFocus will not consider applications that are only a derivative of the research already ongoing in the applicant's laboratory if they are currently in the macular degeneration field. The focus area of retinal degeneration, photoreceptor, and RPE mechanisms is highly relevant.